Prescription Drug Price Relief Act of 2021
Latest action · Mar 23, 2021 Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held. With printed Hearing: S.Hrg. 117-176.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 23, 2021
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Prescription Drug Price Relief Act of 2021
This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs.
Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.
Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population.
The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures.
Cosponsors 6
Members who signed on, in the order they did. All signed on Mar 23, 2021.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-CA | Alex Padilla | Original | Mar 23, 2021 |
| D-MN | Amy Klobuchar | Original | Mar 23, 2021 |
| D-NJ | Cory A. Booker | Original | Mar 23, 2021 |
| D-MA | Elizabeth Warren | Original | Mar 23, 2021 |
| D-NY | Kirsten E. Gillibrand | Original | Mar 23, 2021 |
| D-CT | Richard Blumenthal | Original | Mar 23, 2021 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Health, Education, Labor, and Pensions Committee | Referred Mar 23, 2021 |
| Primary Health and Retirement Security Subcommittee | Hearings Mar 23, 2021 |
Actions 3
Everything that happened, newest first.
- Mar 23, 2021Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held. With printed Hearing: S.Hrg. 117-176.
- Mar 23, 2021Introduced in Senate
- Mar 23, 2021Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 102 | Prescription Drug Price Relief Act of 2019 | Reintroduction of | Jan 10, 2019 |
| HR 2148 | Prescription Drug Price Relief Act of 2021 | Identical bill | Oct 19, 2021 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
- Short Title(s) as Introduced
- Prescription Drug Price Relief Act of 2021
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative remedies
- Asia
- Business records
- Canada
- Civil actions and liability
- Competition and antitrust
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Europe
- France
- Germany
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Health information and medical records
- Inflation and prices
- Intellectual property
- Japan
- Licensing and registrations
- Manufacturing
- Marketing and advertising
- Medical research
- Prescription drugs
- Research and development
- United Kingdom
Text 1
Each version as it was printed, newest first.
- Mar 23, 2021Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.